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ABSTRACT
Background: The current standard of care for newly diagnosed glioblastoma 
(GBM) is surgical resection, followed by radiation therapy (RT) with concurrent and 
adjuvant temozolomide chemotherapy (TMZ-CHT).. The patients outcome is still 
poor. In this study we evaluated hypofractionated radiation therapy (HFRT), instead 
of standard fractionated radiation therapy, with concomitant and adjuvant TMZ 
chemotherapy, in terms of safety and effectiveness.
Methods: Patients with newly diagnosed GBM, Karnofsky performance scale 
(KPS) ≥70, and tumor up to 10 cm underwent maximal feasible surgical resection 
were treated. HFRT consisted of 60 Gy, in daily fractions of 4 Gy given 5 days per 
week for 3 weeks. The primary endpoints were overall survival (OS), progression free 
survival (PFS), and incidence of radiation induced brain toxicity. Secondary endpoint 
was the evaluation of neurocognitive function.
Results: A total of 97 patients were included in this phase II study. The median 
age was 60.5 years (range 23-77 years). Debulking surgery was performed in 83.5% 
of patients, HFRT was completed in all 97 patients, concurrent and adjuvant TMZ in 93 
(95.9%). The median number of TMZ cycles was six (range 1-12 cycles). No severe 
toxicity occurred and the neuropsychological evaluation remained stable. At a median 
follow up time of 15.2 months the median OS time, 1,2-year OS rate were 15.9 months 
(95% CI 14-18), 72.2% (95% CI 62.1-80) and 30.4% (95% CI 20.8-40.6). Age, KPS, 
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MGMT methylation status, and extent of surgical resection were significant factors 
influencing the outcome.
Conclusion: HFRT with concomitant and adjuvant TMZ chemotherapy is an 
effective and safe treatment.
INTRODUCTION
The standard of care for newly diagnosed 
glioblastoma multiforme (GBM) consists of surgical 
resection, followed by radiation therapy (RT) with 
concurrent and adjuvant temozolomide chemotherapy 
(TMZ-CHT). This approach affords a median overall 
survival (OS) time and a two years OS rate of 14.6 months 
and 26.5%, respectively [1, 2]. Although, the addition of 
CHT to RT has led to a survival advantage of two months 
on the average, the results are still unsatisfactory, and 
any improvement in this field is mandatory. Increasing 
evidence indicates that more extensive surgical resection, 
at least ≥80%, is associated with a longer life expectancy, 
which become more prominent when the extent of 
resection (EOR) reaches 95%–100% of the tumor contrast 
enhancement area [3, 4]. To date, all the attempts to 
enhance the efficacy of RT were unsuccessful. Dose 
escalation up to 90 Gy using conventional fractionation 
or stereotactic radiosurgery boost did not lead to any 
improvement in outcome, and in most series local 
recurrence occurred within the high-dose regions [5–10]. 
The impact of hypofractionated radiation therapy (HFRT) 
has been investigated as well. The delivery of a higher dose 
per fraction over a shorter time frame has the advantages 
to achieve an increase in cells killing and a reduction 
in accelerated tumor cell repopulation. The initial 
experiences were carried out in elderly and frail patients 
with the aim to reduce the overall treatment time in this 
poor-prognosis subgroup [11–13]. The patients outcome 
were equivalent to conventional fractionation, although 
a lower total doses were used. More recently, HFRT has 
been employed in newly diagnosed GBM patients with 
a curative aim [14–18]. Retrospective and prospective 
studies showed that this approach shares similar feasibility 
and safety results as standard RT schemes, without a 
growing incidence of neurological toxicity. Nowadays, the 
impact of HFRT should be investigated in the setting of a 
multimodality approach which combines concurrent CHT 
and RT. Consequently, we designed a prospective phase 
II trial consisting of postoperative HFRT with concurrent 
and adjuvant TMZ-CHT, following surgical resection, 
to explore the impact of HFRT on GBM outcome in the 
modern era. Primary endpoints of the study were overall 
survival (OS), progression free survival (PFS), and 
incidence of radiation induced brain toxicity. Secondary 
endpoint was the evaluation of neurocognitive function.
RESULTS
Patients and treatments
From August 2013 to December 2015, out of 125 
HGG patients enrolled into the trial, 97 were newly 
diagnosed GBM. Patients and tumor characteristics are 
shown in Table 1. Debulking surgery was performed in 
80 (82.5%) patients and biopsy in 17 (17.5%). HFRT 
was carried out in all 97 patients. Concurrent and 
adjuvant TMZ was performed in 93 (95.9%) patients 
and omitted in 4 (4.1%) for liver disorders, pulmonary 
distress, or hematologic toxicity. Characteristics and 
intensity of treatments are detailed in Table 2. The 
median follow up time for the whole cohort was 15.2 
months (range 3.2-36.8) and 20.2 months (13.1-36.8) 
for the alive patients.
Progression free survival (PFS) and overall 
survival analyses
The median OS time, and the 1, 2-year OS rate were 
15.9 months (95% CI 14.8-18.2), 72.2% (95%CI 62.1-80) 
and 30.4% (95%CI 20.8-40.6) as shown in Figure 1. At 
the last observation time, 29 (29.9%) patients are alive 
and 68 (70.1%) dead. The median PFS time, and the 1, 
2-year PFS rate were 10.9 months (95% CI 9.6-12.5), 
42.3% (95%CI 32.4-51.8), and 15.2% (95% CI 8.2-24.0), 
respectively as shown in Figure 2.
Prognostic factors analyses
Survival according to prognostic factors, including 
age, gender, KPS, MGMT status, EOR, target volume, and 
number of adjuvant TMZ cycles, was analyzed as well. 
The highest benefit was observed in treated patients with 
age ≤60 years, KPS 100, and RPA class 3. Details are 
shown in Table 3.
Postoperative assessment
No mortality or major peri-operative morbidity 
occurred. Postoperative new neurological deficits were 
observed in eight (8.2%) patients, in two cases recovered 
during RT treatment; they consisted in motor deficit in 
three, hemianopsia in two, aphasia in two, and motor 
deficit plus hemianopsia in one patient.
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Table 1: Patients and tumor characteristics
n %
Patients 97 100
Gender
Female 36 37
Male 61 63
Age (years)
Median (range years) 61 (23-74)
≤60 49 51
61-70 34 35
>70 14 14
KPS
70 6 6
80 25 26
90 35 36
100 31 32
RPA
III 8 8
IV 13 14
V 76 78
Tumor molecular profile
IDH wild type 97 100
MGMT methylated 61 63
MGMT unmethylated 36 37
Number of cerebral lobes involved
1 lobe 56 58
2 lobes 30 31
3 lobes 5 5
Multifocal tumor 6 6
Median Volumes treated cm3 (range cm3)
CTV1 79 (11-197)
PTV1 166 (34-401)
CTV2 127 (11-321)
PTV2 241 (34-510)
Median max SUV [11C]METPET before HFRT 3·6 (0-8·1)
KPS=Karnofsky performance scale; RPA=recursive partitioning analysis; IDH1=isocitrate dehydrogenase; MGMT=O-
6-methylguanine-DNA methyltransferase; CTV=clinical target volume; PTV=planning target volume; HFRT= 
hypofractionated radiation therapy; SUV [11C]METPET= 11 carbonione Methionine-Positron Emission Tomography
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CHT-HFRT side effects
All patients completed the scheduled HFRT plan; a 
transient neurological deterioration was recorded in two 
patients, consisting of partial seizure and aphasia. Grade 
I-II radionecrosis (RN) occurred in 22 (22.7%) patients. 
No Grade III- IV radionecrosis were observed. Fatigue 
was observed in 55 (56.7%) patients during concurrent 
CHT-HFRT. Grade 2-4 hematologic toxicity was recorded 
in 12 (12.9%) patients, in three during concomitant 
treatment and in nine patients during adjuvant TMZ. No 
thromboembolic events or cerebral hemorrhage occurred.
Neuropsychological evaluation
lNeuropsychological scores before and after HFRT 
remained unchanged. The analysis showed no detrimental 
effect of HFRT on cognitive functions (language, short 
and long term verbal and visuo-spatial memory, working 
memory, attentive and executive functions). Particularly, 
a significant performance improvement was detected: 
between T0 and T1 in the copy of the figure test (p 
value<<0.01), in the recall of the complex figure tests (p 
value <<0.01), in the ideomotor apraxia test (p=0.03), and 
in the trail making test part A (p value=0.04); between T1 
Table 2: Characteristics and intensity of treatments
Variables n. %
Surgery: 97 100
GTR 53 55
STR 15 15
PR 12 12
Biopsy 17 17
HFRT: 97 100
Total doses/dose per fraction Gy
 PTV1 60/4 100
 PTV2 42/2·8 100
Number of fractions 15 100
Interruption 0 0
Median duration weeks (range weeks) 3 (2.6-4.1)
Chemotheraphy:
Concomitant temozolomide 93 96
Never started concomitant temozolomide 4 4
Reasons
Liver disfunction 2 2
Pulmonary distress 1 1
Hematologic disorder 1 1
Adjuvant temozolomide 93 96
Never started adjuvant temozolomide 4 4
Reasons
Hematologic toxicity 2 2
Liver disfunction 2 2
Median number of cycles (range) 6 (0-12)
GTR=gross total resection:<1 cm3 of residual tumor volume; STR=subtotal resection:1-10cm3 of residual tumor volume; 
PR=partial resection:>10 cm3 of residual tumor volume; HFRT= hypofractionated radiation therapy; PTV=planning target 
volume
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and T2 in the ideomotor apraxia test (p value=0.02) and 
in the trail making test part B-A (p value=0.01) (Table 4).
Treatment at progression
Brain progression occurred in 77 (79.4%) patients 
and a salvage treatment was performed in 34 (44.2%). 
It consisted in surgery alone in one, radiation therapy 
alone in one, surgery with sequential chemo-radiotherapy 
in five and second line chemotherapy alone in 26. The 
chemotherapeutic agents more frequently used were 
fotemustine and temozolomide. The median survival time 
from progression was 8.5 months (95% CI 5.4-11.4).
DISCUSSION
Based on the results of the phase III EORTC-NCIC 
trial, the current standard treatment for newly diagnosed 
GBM patients consists of radiotherapy with concomitant 
and adjuvant TMZ-CHT [1]. Fractionated conformal three-
dimensional radiotherapy (3DCRT) to a total dose of 60 
Gy in 30 daily fractions of 2 Gy each is employed based 
on the results from previous dose exploratory studies [19]. 
The use of protracted RT schedules harbors the theoretical 
drawback of allowing a cell repopulation, which could 
be of relevance in tumors with a rapid doubling time 
such as GBM [20]. This effect may be seen in routine 
clinical practice as well, where a widely rate of patients, 
up to 10%, discontinues RT for disease progression [1]. 
Hypofractionated radiation therapy (HFRT) offers the 
advantages of achieving an increased cells killing action, 
by the delivery of a higher dose per fraction over a shorter 
time frame, and of reducing the effect of accelerated 
tumor cell repopulation by shrinking the RT treatment 
time. Based on these observations, we designed this phase 
II study to assess the feasibility and the effectiveness of 
HFRT schedule within a multimodal therapeutic approach, 
including concurrent and adjuvant TMZ-CHT, following 
surgical resection. Although the initial study design 
included all grade of HGG, we report here the analysis of 
the newly diagnosed IDH wild type GBM patients only, to 
deal with a highly homogeneous population. To now, few 
data are available in GBM patients on the impact of HFRT 
used to radical doses into a multimodal strategy including 
surgery, concomitant and adjuvant chemotherapy [14–18]. 
The published studies are often phase I investigation, with 
a limited number of cases treated, quite heterogeneous 
for patients and tumors characteristics. However, the 
preliminary results were promising, with a median OS up 
to 20 months in some series, and with a low incidence 
of symptomatic radionecrosis or severe neurologic side 
effects. Table 5 showed some of the most relevant phase 
Figure 1: Overall survival for GBM cases treated with hypofractionated radiotherapy with concurrent and adjuvant 
temozolomide chemotherapy following any entity of surgical resection.
Oncotarget67701www.impactjournals.com/oncotarget
I-II studies about this issue. There is no agreement about 
the optimal HFRT doses to deliver and the schedule 
to employ. With the aim to improve the impact on 
outcome, a therapeutic effective dose greater than that of 
conventional radiotherapy (BED
10
 84Gy vs 72Gy) was 
applied. Our results compare favorably with previous 
reports regarding standard RT treatment [1], with a 
median OS time, 1, 2-year OS rate of 15.8 months, 72.2% 
and 28.5%, and a median PFS time, 1, 2-year PFS rate 
of 10.8 months, 42.3% and 16%, respectively, as shown 
in Table 6. Employing this approach, notwithstanding 
a higher dose on large tumor volume was delivered, all 
patients completed HFRT treatment, no neurological 
deterioration was observed and neurocognitive functions 
remained stable or in some cases improved, as shown by 
neuropsychological evaluation. Published data suggest an 
increased incidence of grade III-IV radionecrosis when a 
high dose per fraction and therapeutic effective doses are 
used, ranging from 3% to 20% according to the various 
scheme utilized [21, 22]. In our analysis only grade I-II 
toxicity was recorded and in no patients grade III-IV was 
detected. Several prognostic factors were investigated. As 
in many other published studies, in our series age was a 
factor strongly influencing survival (p=0.01). The greater 
benefit of treatment was observed in patients younger than 
60 years, with a percentage of 40% alive at two years. 
Along with age, KPS was found to significantly affect 
outcome as well, with more than 50% of patients with 
KPS 100 surviving beyond two years (p=<<0.01). The 
extent of surgical resection has been commonly considered 
as a factor affecting outcome in GBM patients [3, 4, 23]. 
Different methodologies to define the amount of tumor 
removal have been used. In our study, we defined three 
groups of patients in relation to the RTV. A favorable trend 
was observed in case of RTV <10 cm3 that was obtained 
in about 70% of patients (p=0.03). Although an extensive 
surgical resection was performed in the largest number of 
patients treated, no major perioperative morbidity occurred 
and adjuvant treatments was started without delays. 
Literature data proved that postoperative neurological 
functions are crucial elements for patient quality of life 
(QoL) and OS. As reported by McGirt et al, new motor or 
language deficits are associated with significant decreases 
in the median survival of patients with GBM supporting 
the need of coupling maximal tumor resection with 
preservation of neurological integrity [24]. Considering the 
small size of RTV and the absence of major neurological 
deficit, no increase in corticosteroid drugs or AED dosage 
was needed during concomitant chemo-radiotherapy, and 
the HFRT was well tolerated along all treatment period. 
One might speculate that a radiotherapy intensification 
jeopardizes the patient ability of completing an adequate 
Figure 2: Progression Free Survival (PFS) for GBM cases treated with hypofractionated radiotherapy followed any 
entity of surgical resection.
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adjuvant chemotherapy treatment. In our cohort, TMZ 
was successfully administered to 96% of patients, and 
more than 50% of them received more than 6 cycles. In 
addition, salvage treatment at progression was done in 
about 45% of patients and the median survival of patients 
was 8.5 months, clearly higher respect to other series [1, 
2]. We are aware that our study does not reach the power 
of a randomized trial in terms of sample size and longer 
follow up time. Nevertheless, the results shown indicates 
that HFRT is a feasible and safe approach, affording good 
survival rates, and considerable decrease in the treatment 
time (from 6 to 3 weeks), which could be relevant in a 
group with short life expectancy, such as GBM patients. 
Subjects who had the greatest benefit are those with young 
age, good performance status, maximal safe resection, and 
a MGMT methylated tumor. Open questions remain the 
optimal radiation total doses to deliver and the schedule 
to utilize, but HFRT within a multimodal therapeutic 
approach, seems a way forward to improve the outcome 
of patients with glioblastoma.
Table 3: Kaplan-Meyer overall survival according to subgroup analyses
Patients Median 
OS months 
(months 
95%CI)
1-year OS
(95%CI)
2-year OS
(95%CI)
p value 
univariate
HR 
multivariate
(95%CI)
p value 
multivariate
Overall 
survival 97 15.9 (14.8-18.2) 72.2 (62.1-80) 30.4 (20.8-40.6)
Gender
Female 36 15.2 (10-18.2) 58.3 (40.7-72.4) 23.2 (10.5-38.8) 0.24 0.78 0.36
Male 61 16.7 (14.8-21.7) 80.3 (68-88.3) 34.5 (21.6-47.7)
Age
≤60 49 18.4 (14.9-24.8) 79.6 (65.4-88.5) 37.3 (23-51.7) 0.03 1.39 0.28
>60 48 14.9 (12-16.7) 64.6 (49.4-76.3) 23.2 (11.5-37.2)
KPS
70 6 9.1 (7.9-ne) 33.3 (4.6-67.6) 0 <<0.01 0.95 <0.01
80 25 12.7 (10-15.8) 68 (46.1-82.5) 13 (2.7-31.8)
90 35 14.9 (12-16.5) 65.7 (47.6-78.9) 24 (11.1-39.7)
100 31 25.2 (18.4-ne) 90.3 (72.9-96.8) 56.9 (35.2-73.7)
RPA
III 8 nr 100 68.6 (21.3-91.2) 0.02 1.35 0.30
IV 13 15.2 (9.1-ne) 76.9 (44.2-91.9) 26 (6.3-51.7)
V 76 15.7 (12.7-18) 69.3 (57.6-78.4) 27.5 (17-38.9)
EOR
GTR 53 17 (15.2-21.4) 81.1 (67.8-89.4) 31.4 (18.1-45.6) 0.13 1.27 0.04
STR 15 15.9 (9.8-26.4) 73.3 (43.6-89.1) 35.6 (12.1-60.3)
PR 12 14.8 (8.8-21.5) 75 (40.9-91.2) 13.9 (0.9-44.1)
Biopsy 17 9.3 (7-ne) 41.2 (18.6-62.6) 29.4 (10.7-51.2)
MGMT
Methylated 61 18 (14.8-21.7) 75.4 (62.6-84.4) 35.4 (22.7-48.4) 0.07 0.58 0.04
Unmethylated 36 14.9 (11.8-16.7) 66.7 (48.8-79.5) 21.8 (9.1-38.1)
KPS= Karnofsky performance scale; RPA=recursive partitioning analysis; EOR=extent of resection;
GTR=gross total resection:<1 cm3 of residual tumor volume; STR=subtotal resection:1-10cm3 of residual tumor volume;
PR=partial resection:>10 cm3 of residual tumor volume; MGMT=O-6-methylguanine-DNA methyltransferase; nr=not 
reached; ne=not evaluable.
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Table 4: Neuropsychological outcome
Cognitive 
domains
Test T0 T1 T2 T3
Before 
HFRT
1 month after HFRT 6 months after 
HFRT
12 months after 
HFRT
n. mean n. mean p value
(T0-T1)
n. mean p value
(T0-T2)
n. mean p value
(T0-T3)
Language Token 85 29.1 80 29.7 0.1 33 28.5 0.2 12 28.5 0.50
Picture Naming 85 42.2 85 43.7 0.07 33 43.5 0.43 12 42.9 0.71
Fonological fluency 75 20.5 73 22.6 0.12 31 20.3 1.0 11 20.2 0.95
Semantic Fluency 74 29.7 73 32.6 0.05* 31 32.1 0.13 11 32.7 0.21
Memory Digit span forward 85 5.0 79 5.1 0.31 32 4.9 0.68 11 4.8 1.00
Corsi span forward 85 4.0 80 4.1 0.22 34 4.3 0.18 11 4.0 0.75
Digit span 
backward 85 3.2 79 3.4 0.14 33 3.5 0.93 11 3.4 0.63
Corsi span 
backward 84 3.5 80 3.7 0.11 32 3.7 0.80 12 3.4 0.45
Rey’s 15 words test 
- immediate 72 29.7 67 30.4 0.42 29 29.8 0.32 11 31.8 0.29
Rey’s 15 words test 
- delayed 72 5.0 66 5.1 0.96 28 5.1 0.53 11 5.5 0.55
Recall complex 
figure
78 9.8 78 12.0 <<0.01* 32 13.4 0.01 12 12.9 0.20
Visuo-
constuctional 
abilities
Copy of the figure 78 25.7 78 28.1 <<0.01* 31 27.7 0.49 12 29.3 0.24
Apraxia Ideomotor apraxia 85 66.0 79 66.2 0.03* 31 67.4 0.02* 12 56.2 0.33
Orofacial apraxia 84 19.2 78 19.4 0.16 31 19.3 0.30 12 19.2 0.32
Attention 
and executive 
functions
Trail Making test 
- a 34 54.9 38 50.1 0.04* 23 52.7 0.78 8 44.6 0.32
Trail Making test 
- b 31 169.8 37 168.8 0.08 21 157.8 0.06 6 150.2 0.18
Trail Making test 
- b-a 31 114.8 37 123.5 0.26 21 105.9 0.01* 6 108.1 0.18
Attentive matrices 84 41.3 80 41.6 0.37 33 40.7 0.70 12 37.4 0.08
Stroop Test - error 70 2.0 72 1.2 0.30 28 1.8 0.62 10 2.9 0.95
Stroop Test - time 70 28.7 72 28.9 0.56 28 35.1 0.71 10 52.3 0.41
Raven coulored 
progressive 
matrices
80 26.3 74 27.2 0.24 31 27.6 0.22 10 29.1 0.47
HFRT=hypofractionated radiation therapy; N=number of patients; mean= age-education-adjusted score for each test and for 
each time point;
T0: before HFRT; T1:1 month after HFRT; T2:6 months after HFRT; T3:12 months after HFRT; * significant p values 
(p ≤ 0·05)
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Table 5: Published studies regarding hypofractionated radiation therapy
Authors N pts Study design Concurrent 
and adjuvant 
TMZ
Total dose N frs RN Median OS 1 year
OS %
2 years
OS %
Chen (14) 16 Phase I yes 60 Gy 20
15
12
10
1 G4
3 G3
16.3 months nr nr
Terasaky (16) 26 Pilot yes 45 Gy 15 no 15.6 months nr nr
Reddy (15) 24 Phase II yes 60 Gy
30 Gy
10
10
no 16.6 months nr nr
Jastaniyah (17) 25 Phase I yes 60 Gy 22 no 15.7 months 62 9
Iuchi (18) 46 Phase II yes 68 Gy
40 Gy
32 Gy
8
8
8
20 
G3
20 months 50 41
Pts=patients; TMZ=temozolomide; frs=fractions; RN=radionecrosis; OS=overall survival; no=not observed; nr=not 
reported
Table 6: comparison between standard (6 weeks) radiation therapy (Stupp et al. [1]) and hypofractionated (3 weeks) 
radiation therapy within multimodal approach
Variables Concurrent and adjuvant TMZ CHT
with standard RT
(60 Gy in 30 fractions)
Concurrent and adjuvant TMZ CHT
with hypofractionated RT
(60 Gy in 15 fractions)
Extent of surgery
Biopsy 17% 17.5%
Debulking 83% 82.5%
Radiotherapy
Never started 1% 0%
Early discontinuation* 10% 0%
Concurrent TMZ CHT
Never started 2% 4.1%
Adjuvant TMZ CHT
Never started 22% 4%
Number of median 
cycles (range) 3 (0-7) 6 (0-12)
PFS (95%CI) (95%CI)
Median 6.9 months (5.8-8.2 ) 10.9 months (9.6-12.5)
1year 26.9% (21.8-32.1) 42.3% (32.4-51.8)
2 year 10.7% (7.0-14.3) 15.2% (8.2-24.0)
OS
Median 14.6 months (13.2-16-8) 15.9 months (14.8-18.2)
1 year 61.1% (55.4-66.7) 72.2% (62.1-80)
2 year 26.5% (21.2-31.7) 30.4% (20.8-40.6)
*for disease progression
TMZ=temozolomide; CHT=chemotherapy; PFS=progression free survival; OS= overall survival
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MATERIALS AND METHODS
Study design and patients
The present trial was a prospective single arm phase 
II study approved by our institutional review board. The 
trial was registered at ClinicalTrials.gov site with number 
NCT00006353. All patients provided a written informed 
consent to the treatment and the use of their data for 
scientific purposes. Eligible patients had: 1) an age of 
18-70 years and a Karnofsky performance scale (KPS) 
≥60; 2) a newly diagnosed high grade gliomas (HGG); 
3) a residual tumor or surgical cavity with a maximum 
diameter of 10 cm; 4) a normal liver, kidney and bone 
marrow functions. A limited number of patients older than 
70 years with KPS ≥80 were included as well. We report 
here the analysis of GBM patient population group only.
Procedures
Surgery
Surgery was performed in all patients with the aim 
to maximally remove the tumor according to functional 
boundaries. Tumor removal was achieved with the aid of 
brain mapping techniques and imaging neuro-navigation 
(post contrast T1 weighted images, MET-PET, FLAIR, 
functional MRI, DTI) coupled with intraoperative 
ultrasounds, to afford maximal resection and maintenance 
of full patient functional integrity. Extent of resection 
(EOR) was determined by comparing preoperative post-
contrast T1 weighted MRI with postoperative MRI study, 
acquired within 48 hours after surgery, and calculated 
as follows: preoperative tumor volume – postoperative 
tumour volume/preoperative tumor volume. Gross total 
resection (GTR) was defined as residual tumor volume 
(RTV) lower than 1 cm3, subtotal resection (STR) when 
RTV was among 1 and 10 cm3, and partial resection 
(PR) when it was greater than 10 cm3 [25]. Patients who 
received biopsy only were also enrolled. Tumor molecular 
profile was available in all cases. Immunohistochemical 
staining for Isocitrate dehydrogenase (IDH1/2) was 
performed on BenchMark XT automated tissue staining 
systems (Ventana Medical Systems, Inc., Tucson, AZ) 
using validated protocols. O-6-methylguanine-DNA 
methyltransferase (MGMT) promoter methylation 
status was determined by pyrosequencing (Diatech 
Pharmacogenetics, MGMT plus, valid CE/IVD) [26].
Hypofractionated radiation therapy (HFRT)
CT scan, T1-weighted FLAIR (fluid-attenuated 
inversion recovery images) and T2-weighted 3D-FLAIR 
followed by T1-weighted MPRAGE MRI and [11C]-
Methionine-PET (11CMETPET) were acquired for 
radiation therapy planning and images were co-registered 
each other. Pre and post-operative MRI acquired within 
48 hours from surgery were used too to better define the 
target RT volume. Two different clinical target volume 
(CTV) were outlined: CTV1 corresponded to the entire 
surgical cavity plus eventual residual tumor after surgery 
or, to the abnormality on the T1-weighted post-contrast 
MPRAGE and 11CMETPET in case of biopsy; CTV2 
corresponded to the abnormality on FLAIR MRI images 
before surgery. Planning target volume 1-2 (PTV1/PTV2) 
was generated adding an isotropic margin of 5 mm from 
CTV1 and CTV2 respectively. Intensity modulated 
radiation therapy was performed within 4-6 weeks after 
surgery using volumetric modulated arc therapy (VMAT). 
The dose prescribed was 60 Gy with daily fraction of 4 
Gy on PTV1, and 42 Gy with daily fraction of 2.8 Gy 
on PTV2 for 15 consecutive days, using a simultaneous 
integrated boost (SIB). Organs at risk (OARs) outlined 
were optic nerves and chiasm, lens, brainstem and 
cochlea without additional margins, and the recommended 
maximal doses were ≤40 Gy, ≤10 Gy, ≤30 Gy, and ≤30 
Gy, respectively. Dose was prescribed to an isodose line 
that ensured that more than 98% of PTV1-2 receives 95% 
of prescribed dose. In each session, patients position check 
was performed using ExacTrac (Brain Lab) system and 
cone beam computer tomography (CBCT).
Chemotherapy
All patients received TMZ concurrently with HFRT. 
TMZ was administered orally, once daily, at 75 mg/m2, 
starting on the first day of HFRT and continuing for the 
whole treatment. After a 4-week break adjuvant TMZ was 
administered at 150 to 200 mg/m2 orally, once daily, for 5 
consecutive days every 28 days up to 12 cycles, or until 
disease progression occurred.
Supportive care
Corticosteroids were administered during the whole 
HFRT treatment and progressively reduced at the end of 
RT. Antiepileptic drugs (AEDs) were prescribed only in 
patients with a history of at least one seizure. The most 
frequently used AEDs were levetiracetam as first line 
instance followed by topiramate, lamotrigine or lacosamide.
Evaluation of clinical outcome
Clinical outcome was evaluated by neurological 
examination and MRI imaging 1 months after concurrent 
CHT-HFRT and every four months thereafter. [11C]
MET-PET was performed at four and 12 months during 
maintenance CHT or to rule out pseudo-progression. 
When needed tumor progression was defined according 
to Response Assessment in Neuro-Oncology (RANO) 
working group [27]. Thirty-days postoperative morbidity 
and mortality were assessed. Major complications were 
defined as the appearance of new neurological deficits 
persisting for more than 30 days after surgery and requiring 
a prolonged hospitalization or rehabilitation. All other 
complications were defined as minor. The appearance 
of new deficits or the worsening of preoperative deficits 
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were considered as complications. Hematologic and 
non-hematologic toxicities, including radionecrosis, 
were graded according to Common Terminology Criteria 
for Adverse Events version 3.0. Neuropsychological 
assessment was performed through a shortened version 
of the “Milano Bicocca Battery”, evaluating language, 
memory, apraxia, visuo-constructional abilities, 
attentive and executive functions [28]. The total time of 
administration was one hour on average. Patients were 
evaluated one week before the start of HFRT (T0), 1 (T1), 
6 (T2) and 12 months (T3) thereafter or until disease 
progression.
Statistical analysis
The study was designed to demonstrate, with 90% 
power and 1 sided α error of 5%, a significant difference 
between a reference value of 1 year survival of 55.2% in 
standard treatments compared to a figure of 71.4% for 
the new one. Variables considered were: gender, age, 
KPS status, RPA class, EOR and MGMT methylated 
status. Age of patients was divided into two groups, 
respectively, ≤ 60 and >60 years. Survival and recurrence 
time observations were evaluated according to the method 
of Kaplan and Meier, starting from the date of diagnosis. 
The median survival time is evaluated obtained from Ŝ(t), 
the Kaplan –Meier product-limit estimate of the survivor 
function. Confidence bounds of the survivor function are 
calculated based on the asymptotic variance of ln[−ln 
Ŝ(t), as described in Kalbfleisch and Prentice. The upper 
(lower) confidence limits for the median survival times 
are defined as the first time at which the upper (lower) 
confidence limit for Ŝ(t) is less than or equal to 0.5. A 
not reached indicator (nr) was specified if the survival 
estimate resulted above the 50% level in the considered 
observation time. Upper confidence bound of median 
survival time was labeled as ne if not evaluable with 
the above method for a specific group of patients in the 
considered time of observation. In order to assess the 
prognostic role of the different individual variables, the 
log-rank test was used for dichotomous variables gender, 
MGMT and age (grouped). Univariate cox model was 
applied for the remaining variables. Multivariate Cox 
regression model was used as a method to estimate the 
independent association of our variable set with overall 
survival. Neurophysiological assessment parameters 
were preliminarily evaluated for a difference before 
and after RT. In order to assess the effect of the HFRT 
on neurocognitive functions a series of nonparametric 
analyses (Wilcoxon signed-rank test) was performed. P 
value and the mean of the age- and education-adjusted 
score for each test and for each time point (T0;T1;T2;T3) 
was reported. Statistical analysis was performed by the use 
of the Stata software, version 13.1 (Stata Corp LP, College 
Station TX USA). Methods and calculation details can 
also be found in the software refence manual in the stata 
website (http://www.stata.com/).
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